How has been the historical performance of Ajooni Biotech?

Answer:The historical performance of Ajooni Biotech shows a consistent growth in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025.

Breakdown:
Ajooni Biotech's net sales have risen from 39.72 Cr in March 2019 to 114.69 Cr in March 2025, demonstrating a strong upward trend. Total operating income has similarly increased, reaching 114.69 Cr in March 2025 from 40.06 Cr in March 2019. The raw material cost has also grown, reflecting the company's expanding operations, with costs rising from 36.46 Cr in March 2019 to 97.15 Cr in March 2025. Operating profit (PBDIT) has shown improvement, increasing from 0.89 Cr in March 2019 to 5.75 Cr in March 2025, although the operating profit margin has fluctuated, peaking at 4.16% in March 2022 before settling at 3.21% in March 2025. Profit before tax has increased from 0.47 Cr in March 2019 to 4.33 Cr in March 2025, while profit after tax has also risen significantly from 0.41 Cr to 3.37 Cr over the same period. The company's total assets have grown from 17.13 Cr in March 2019 to 47.21 Cr in March 2024, while total liabilities have decreased from 58.46 Cr in March 2023 to 47.21 Cr in March 2024, indicating improved financial health. Cash flow from operating activities has been negative in recent years, but cash flow from investing activities turned positive in March 2024, suggesting strategic investments. Overall, Ajooni Biotech has shown a positive trajectory in sales and profitability, alongside a strengthening balance sheet.